"...identified a protein critical to the survival of triple-negative breast cancer (TNBC) patients. This breakthrough research has the potential to cure TNBC by targeting a protein called RSK2, which eliminates TNBC cells completely. The study, published June 5, 2012 in Stem Cells medical journal, reports that RSK2 inhibitors have the ability to kill all of the cells including cancer stem cells which give rise to cancer recurrence. This cutting-edge discovery will potentially personalize the treatment of TNBC on an international scale.
"RSK2 inhibition provides a novel therapeutic avenue for TNBC and holds the promise of being one of the first targeted therapies for this challenging form of breast cancer," says Dr. Sandra Dunn, UBC."
http://www.prweb.com/releases/CBCF/TNBCannoucement/prweb9576703.htm
(click link for full article)
